|
US8598156B2
(en)
*
|
2010-03-25 |
2013-12-03 |
Glaxosmithkline Llc |
Chemical compounds
|
|
US20140227289A1
(en)
*
|
2011-05-13 |
2014-08-14 |
Stephen Michael Cohen |
Compounds and methods for treating insulin resistance syndrome
|
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
|
HRP20190135T1
(hr)
|
2011-07-19 |
2019-03-22 |
Merck Sharp & Dohme B.V. |
4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
|
|
US9550750B2
(en)
|
2012-10-05 |
2017-01-24 |
Merck Sharp & Dohme Corp. |
Indoline compounds as aldosterone synthase inhibitors
|
|
MX2015009270A
(es)
*
|
2013-01-18 |
2015-10-30 |
Hoffmann La Roche |
Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
|
|
ES2638317T3
(es)
*
|
2013-04-04 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Nuevos derivados de N-(2,3-dihidro-1H-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina y N-(2,3-dihidro-1H-indol-5-il)-4-quinazolinamina como inhibidores de PERK
|
|
TWI482757B
(zh)
*
|
2013-10-07 |
2015-05-01 |
Luminescence Technology Corp |
Ｖｅｇｆ－２／３受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途
|
|
WO2015056180A1
(en)
*
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
AU2014358868A1
(en)
|
2013-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
|
|
US10272083B2
(en)
|
2014-01-21 |
2019-04-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
|
|
JP2017507967A
(ja)
*
|
2014-03-11 |
2017-03-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
Ｐｅｒｋ阻害剤として作用する化合物
|
|
US9937171B2
(en)
|
2014-04-11 |
2018-04-10 |
Acerta Pharma B.V. |
Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
|
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
|
PT3179991T
(pt)
|
2014-08-11 |
2021-11-26 |
Acerta Pharma Bv |
Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
|
|
CA2965517C
(en)
*
|
2014-10-24 |
2023-05-02 |
Bristol-Myers Squibb Company |
Indole carboxamides compounds useful as kinase inhibitors
|
|
WO2016075224A1
(en)
|
2014-11-14 |
2016-05-19 |
Nerviano Medical Sciences S.R.L. |
6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
|
|
WO2016126026A2
(ko)
*
|
2015-02-04 |
2016-08-11 |
서울대학교병원 |
당뇨병 치료 조성물 및 이의 용도
|
|
WO2017002095A1
(en)
|
2015-07-02 |
2017-01-05 |
Acerta Pharma B.V. |
Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
|
|
WO2017046739A1
(en)
*
|
2015-09-15 |
2017-03-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Imidazolidinone derivatives as inhibitors of perk
|
|
TW201722957A
(zh)
*
|
2015-09-15 |
2017-07-01 |
葛蘭素史克智慧財產（第二）有限公司 |
化學化合物
|
|
AU2017247798C1
(en)
*
|
2016-04-07 |
2020-08-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
HUE056135T2
(hu)
*
|
2016-04-15 |
2022-01-28 |
Cancer Research Tech Ltd |
RET kináz inhibitor heterociklusos vegyületek
|
|
US11026945B2
(en)
*
|
2016-04-29 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
|
|
WO2017216792A1
(en)
|
2016-06-13 |
2017-12-21 |
Ramot At Tel-Aviv University Ltd. |
Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
|
|
RU2753520C2
(ru)
|
2016-06-21 |
2021-08-17 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы
|
|
US20190241573A1
(en)
*
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
WO2018055578A1
(en)
*
|
2016-09-22 |
2018-03-29 |
The University Of Hong Kong |
Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases
|
|
WO2018138358A1
(en)
|
2017-01-30 |
2018-08-02 |
Université de Liège |
Perk and ire-1a inhibitors against neurodevelopmental disorders
|
|
CN106974910B
(zh)
*
|
2017-03-02 |
2019-11-12 |
深圳大学 |
含索拉非尼和gsk2656157的药物组合物及用途
|
|
CN106963769B
(zh)
*
|
2017-03-03 |
2019-10-25 |
深圳大学 |
含pi3k抑制剂和perk抑制剂的药物组合物及其应用
|
|
FI3593817T3
(fi)
*
|
2017-03-06 |
2025-02-05 |
Tsubota Lab Inc |
Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
|
|
ES2747768T3
(es)
*
|
2017-03-20 |
2020-03-11 |
Forma Therapeutics Inc |
Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
|
|
WO2019021208A1
(en)
*
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
MX2020004557A
(es)
|
2017-11-02 |
2020-10-05 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
|
CN108003163B
(zh)
*
|
2017-11-30 |
2020-11-24 |
武汉九州钰民医药科技有限公司 |
用作激酶抑制剂的吡唑并嘧啶类化合物及其应用
|
|
CN111100130B
(zh)
*
|
2018-10-29 |
2022-07-15 |
四川大学 |
4-氨基吡咯并嘧啶衍生物及其制备方法和用途
|
|
CN111213632B
(zh)
*
|
2019-11-19 |
2022-03-01 |
长春中医药大学 |
动物药环氧树脂标本制作方法
|
|
CA3186041A1
(en)
|
2020-06-08 |
2021-12-16 |
Halia Therapeutics, Inc. |
Inhibitors of nek7 kinase
|
|
WO2022140246A1
(en)
|
2020-12-21 |
2022-06-30 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
WO2022212326A1
(en)
|
2021-03-29 |
2022-10-06 |
Halia Therapeutics, Inc. |
Nek7 inhibitors
|
|
EP4320127A1
(en)
|
2021-04-05 |
2024-02-14 |
Halia Therapeutics, Inc. |
Nek7 inhibitors
|
|
WO2023034236A1
(en)
*
|
2021-08-31 |
2023-03-09 |
Wisconsin Alumni Research Foundation |
Deuterated inhibitors of rip kinases
|
|
GB202407386D0
(en)
|
2024-05-24 |
2024-07-10 |
Apollo Ap45 Ltd |
1H-pyrazolo(4,3-D)pyrimidine derivatives
|